Publications
5540 Results
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 4562); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1500
Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell (pRCC) Carcinoma: an Analysis from the SWOG S1500 (PAPMET) Trial
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 4158); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 2504); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Change in RECIST Tumor Size Correlates Linearly with Survival in Patients Treated with Checkpoint Inhibitor Therapy (SWOG S1609)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 11516); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors (Cohort 27)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5517); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Vulvar Cancers
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5036); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1802
HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) (SWOG S1802)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS4608); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), tips, poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1937
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS9603); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr e18566); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Rural cancer care delivery during the COVID-19 pandemic for patients with early-stage cancer
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr e13595); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery